Pharma Reviews: Indian firms unlikely to be hit by USFDA's red flag on antacid medicines

After high blood pressure drug (sartan), the same carcinogenic impurity is back to haunt the global pharma industry once again, this time for antacid ...
Read more: Indian firms unlikely to be hit by USFDA's red flag on antacid medicines